Improved health status with insulin degludec compared with insulin glargine in people with Type1 diabetes

Diabetic Medicine

Volumn 29, Issue 6, 2012, Pages 716-720

  Home, P D ^a   Meneghini, L ^b   Wendisch, U ^c   Ratner, R E ^d   Johansen, T ^e   Christensen, T E ^e   Jendle, J ^f   Roberts, A P ^g   Birkeland, K I ^h  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Gründungsvorsitzender der Arbeitsgemeinschaft Diabetes und Migranten   (Germany)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e NOVO NORDISK A S   (Denmark)

^f ÖREBRO UNIVERSITY   (Sweden)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

Hypoglycaemia; Insulin; Insulin therapy; Quality of life; Type1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMOTION; EVENING DOSAGE; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MENTAL HEALTH; NOCTURNAL HYPOGLYCEMIA; OPEN STUDY; PAIN; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT DURATION; WELLBEING;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH SURVEYS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861130120     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03547.x     Document Type: Article

References (17)

1. Rubin RR, Peyrot M. Psychological issues and treatments for people with diabetes. J Clin Psychol 2001; 57: 457-478.
2. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009; 164: 6-10.
3. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type2 diabetes. Prim Care Diabetes 2010; 4: S11-S18.
4. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33: 240-245.
5. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
6. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-1534.
7. Vexiau P, Mavros P, Krishnarajah G, Lyu R, Yin D. Hypoglycaemia in patients with type2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008; 10: S16-S24.
8. Lundkvist J, Berne C, Bolinder B, Jönsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005; 6: 197-202.
9. Jermendy G; Hungarian RECAP Group. Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type2 diabetes in Hungary. Health Qual Life Outcomes 2008; 6: 88.
10. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
11. Jonassen I, Havelund S, Ribel U, Hoeg-Jensen T, Steensgaard DB, Johansen T et al. Insulin degludec is a new generation ultra-long-acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes 2010; 59: A11.
12. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia 2010; 53: S387.
13. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA et al. Insulin degludec in type1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
14. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's Manual for the SF-36v2(R) Health Survey. 2nd edn. Lincoln, RI: QualityMetric Incorporated, 2007.
15. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.
16. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on diabetes management and work productivity. Value Health 2011; 14: 665-671.
17. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type2 diabetes mellitus. Diabetes Res Clin Pract 2011; 91: 363-370.